IBAB Ion Beam Applications SA

IBA and Wallonie Entreprendre International secure 30% stake in mi2-factory to support improved efficiency of silicon carbide-powered devices

IBA and Wallonie Entreprendre International secure 30% stake in mi2-factory to support improved efficiency of silicon carbide-powered devices

 

Louvain-La-Neuve, Belgium, 21 January 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and Wallonie Entreprendre International (WE International), the international branch of the Walloon public investment company, today announce a joint strategic investment of EUR 5 million each in mi2-factory, a start-up and spin-off from the University of Applied Sciences Jena, Germany. This investment secures a 15% stake for IBA and a 15% stake for WE International.

mi2-factory specializes in nitrogen implantation in silicon carbide (SiC), an important process to improve the efficiency of SiC power semiconductor chips. Those chips are essential components in modern power electronic systems serving in a range of sectors, including electric mobility, energy generation from wind and solar, renewable energy grids, among others. The company focuses on high-energy implantation to simplify processes, reduce cost, and enhance yield and quality of SiC chips and wafers.

In line with its strong commitment to innovation, IBA is proud to support mi2-factory in advancing its lab-proven process towards industrial-grade solution. IBA’s advanced compact particle accelerator technologies are ideally suited to meet mi2’s ambitions of enabling SiC devices that combine the best attributes  of quality, cost, and production capacity.

The development of mi2-factory is further supported by a grant from the Important Project of Common European Interest for Microelectronics and Communication Technologies (IPCEI ME/CT) and equity investment from the company’s current shareholders bringing its total additional resources to approximately EUR 40 million. Beyond the economic prospects that the development of this type of solution represents, the project also marks a potential advancement in strengthening European expertise in the strategic and rapidly growing field of power electronics.

Prof. Dr. Michael Rüb, CEO & Managing Director of mi2-factory, commented: “mi2-factory was seeking not only strategic and technological partners but also co-investors to strengthen our position in IPCEI projects. Partnering with IBA, the world leader in particle accelerator technologies, and Wallonie Entreprendre International, a reputable institutional partner, reinforces our expertise and know-how, positioning us as the best in class in high-energy nitrogen implantation in silicon carbide as we look to advance towards an industrial grade solution.”

Henri de Romrée, Deputy Chief Executive Officer of IBA, added: “Investing in promising companies like mi2-factory is part of our entrepreneurial DNA and could lead to potential new applications for our accelerators. We look forward to collaborating with the talented mi2-factory team and contributing to this project to help grow European expertise in power electronics, which is an important and strategic sector.”

Laurence Glautier, General Manager of WE International, commented : " We are proud to make this co-investment alongside IBA, a long-standing partner with a proven track record of innovation and a strong impact on the Walloon region. This investment in a European project, backed by IPCEI, aligns perfectly with our mission to support high-value-added initiatives that foster Walloon expertise in cutting-edge sectors like semiconductor in power electronics. By encouraging IBA's diversification into this strategic domain, we not only reinforce technological advancements but also ensure long-term economic growth and skilled employment opportunities in Wallonia.”

***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).-More information can be found at:

About Wallonie Entreprendre International

WE International (Wallonie Entreprendre International S.A.) is the international branch of the Walloon public investment company Wallonie Entreprendre S.A. For more than 20 years, WE International is dedicated to finance Walloon companies with projects abroad that generate significant economic benefits for the Walloon region. More information can be found at :

About mi2-factory

mi2-factory GmbH (“mi2-factory”) offers a novel process technology for semiconductor production with its innovative EFIITRON wafer processing equipment. Chip manufacturers use EFIITRON to reduce chip costs, to increase reliability and to realize new component and wafer architectures.

The customer benefits from previously unattainable precision and flexibility. This enables a cost reduction of up to 50% for silicon carbide (SiC) chips. EFIITRON is targeting the strategic market of silicon carbide power electronics for e-mobility, renewable energy applications, AI data centers, traction and industrial drives. Well-known studies expect a market volume in 2027 of > $6 billion with a CAGR of 30-40%. mi2-factory is targeting to process more than 30% of all SiC wafers with EFIITRON equipment in the long term.

More information on mi2, at

More information on IPCEI ME/CT, at:

For further information, please contact:

IBA

Olivier Lechien

Corporate Communication Director



For media and investor enquiries:

ICR Healthcare

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
21/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 2nd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effect...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 2 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à parti...

 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 25, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 13, 2026. In its notification, Premier Miton Group plc indi...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 25 février 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçue le ...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 23rd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 20...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch